GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (FRA:TG1N) » Definitions » Shiller PE Ratio

Armata Pharmaceuticals (FRA:TG1N) Shiller PE Ratio : (As of Jun. 04, 2024)


View and export this data going back to . Start your Free Trial

What is Armata Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Armata Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Armata Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals Shiller PE Ratio Chart

Armata Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Armata Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Armata Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Armata Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Armata Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Shiller PE Ratio falls into.



Armata Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Armata Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Armata Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.635/131.7762*131.7762
=-0.635

Current CPI (Mar. 2024) = 131.7762.

Armata Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 215.352 100.560 282.204
201409 358.510 100.428 470.418
201412 -665.340 99.070 -884.993
201503 -451.464 99.621 -597.185
201506 41.164 100.684 53.876
201509 -37.422 100.392 -49.121
201512 -69.400 99.792 -91.643
201603 -103.341 100.470 -135.541
201606 -97.436 101.688 -126.266
201609 -40.291 101.861 -52.124
201612 -100.866 101.863 -130.487
201703 -25.394 102.862 -32.532
201706 -18.192 103.349 -23.196
201709 -1.057 104.136 -1.338
201712 -0.473 104.011 -0.599
201803 -2.725 105.290 -3.411
201806 -2.277 106.317 -2.822
201809 -0.514 106.507 -0.636
201812 1.330 105.998 1.653
201903 -0.708 107.251 -0.870
201906 -0.611 108.070 -0.745
201909 -0.663 108.329 -0.806
201912 -0.432 108.420 -0.525
202003 -0.443 108.902 -0.536
202006 -0.231 108.767 -0.280
202009 -0.263 109.815 -0.316
202012 -0.296 109.897 -0.355
202103 -0.227 111.754 -0.268
202106 -0.208 114.631 -0.239
202109 -0.187 115.734 -0.213
202112 -0.204 117.630 -0.229
202203 -0.272 121.301 -0.295
202206 -0.246 125.017 -0.259
202209 -0.242 125.227 -0.255
202212 -0.274 125.222 -0.288
202303 -0.374 127.348 -0.387
202306 -0.157 128.729 -0.161
202309 -0.806 129.860 -0.818
202312 -0.504 129.419 -0.513
202403 -0.635 131.776 -0.635

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Armata Pharmaceuticals  (FRA:TG1N) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Armata Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Armata Pharmaceuticals (FRA:TG1N) Business Description

Traded in Other Exchanges
Address
4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Armata Pharmaceuticals (FRA:TG1N) Headlines

No Headlines